胰高血糖素样肽-1 受体激动剂（GLP-1 RA）治疗相关嗜酸性粒细胞疾病：病例报告及文献复习。
Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.
机构信息
Universidad Icesi, Facultad de Ciencias de la Salud, Cali, 760031, Colombia.
Unit of Rheumatology, Fundación Valle del Lili, Unidad de Reumatología, Cali, 760031, Colombia.
出版信息
Clin Rheumatol. 2023 Sep;42(9):2501-2506. doi: 10.1007/s10067-023-06612-w. Epub 2023 May 18.
Abstract
Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.
摘要
胰高血糖素样肽-1 受体激动剂（GLP-1 RA）是一类在药理学组成和与人 GLP-1 的同源性方面存在差异的药物，最常用于治疗 2 型糖尿病和减肥。有孤立的报告称与 GLP-1 RA 相关的嗜酸性不良反应。我们报告了一例 42 岁女性患者的病例，她在开始每周皮下注射司美格鲁肽后，出现了嗜酸性筋膜炎，在停用司美格鲁肽和开始免疫抑制后，临床病情好转。本文还回顾了之前报道的与 GLP-1 RA 相关的嗜酸性不良反应事件。
相似文献
1
Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.
Clin Rheumatol. 2023 Sep;42(9):2501-2506. doi: 10.1007/s10067-023-06612-w. Epub 2023 May 18.
2
Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.
Clin Toxicol (Phila). 2024 Feb;62(2):131-133. doi: 10.1080/15563650.2024.2322049. Epub 2024 Mar 12.
3
Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
Obes Rev. 2022 Jun;23(6):e13435. doi: 10.1111/obr.13435. Epub 2022 Feb 22.
4
Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
Diabetes Obes Metab. 2023 Nov;25(11):3223-3234. doi: 10.1111/dom.15219. Epub 2023 Aug 2.
5
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Curr Cardiol Rep. 2018 Sep 26;20(11):113. doi: 10.1007/s11886-018-1051-2.
6
Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Ann Pharmacother. 2018 Dec;52(12):1224-1232. doi: 10.1177/1060028018784583. Epub 2018 Jun 22.
7
GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Pharmacotherapy. 2014 Nov;34(11):1174-86. doi: 10.1002/phar.1507.
8
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
9
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Cardiovasc Res. 2023 May 2;119(4):886-904. doi: 10.1093/cvr/cvac112.
10
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.
引用本文的文献
1
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation.
Front Immunol. 2025 Jul 15;16:1610368. doi: 10.3389/fimmu.2025.1610368. eCollection 2025.
2
GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity.
Open Biol. 2025 Jan;15(7):240303. doi: 10.1098/rsob.240303. Epub 2025 Jul 2.
3
A Closer Look at the Dermatological Profile of GLP-1 Agonists.
Diseases. 2025 Apr 22;13(5):127. doi: 10.3390/diseases13050127.
4
A Review of Glucagon-like Peptide-1 in Dermatology.
J Clin Aesthet Dermatol. 2025 Mar;18(3):42-50.
5
Hypereosinophilic syndrome: a rare cause of ST-elevation myocardial infarction and thrombus formation on the aortic valve.
BMJ Case Rep. 2024 Apr 16;17(4):e259494. doi: 10.1136/bcr-2023-259494.
本文引用的文献
1
Semaglutide-Associated Acute Interstitial Nephritis: A Case Report.
Kidney Med. 2022 Oct 29;4(12):100561. doi: 10.1016/j.xkme.2022.100561. eCollection 2022 Dec.
2
Semaglutide-associated bullous pemphigoid.
JAAD Case Rep. 2021 Aug 5;15:107-109. doi: 10.1016/j.jdcr.2021.07.027. eCollection 2021 Sep.
3
Bullous Pemphigoid Triggered by Liraglutide.
Cutis. 2021 May;107(5):E9-E11. doi: 10.12788/cutis.0262.
4
Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.
Ann Dermatol. 2020 Jun;32(3):230-232. doi: 10.5021/ad.2020.32.3.230. Epub 2020 Apr 24.
5
Acute Kidney Injury Associated With Semaglutide.
Kidney Med. 2021 Jan 7;3(2):282-285. doi: 10.1016/j.xkme.2020.10.008. eCollection 2021 Mar-Apr.
6
Liraglutide-Induced Hepatotoxicity.
Biomedicines. 2021 Jan 22;9(2):106. doi: 10.3390/biomedicines9020106.
7
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
8
An unusual case of a generalised cutaneous drug reaction to liraglutide.
Eur J Dermatol. 2019 Dec 1;29(6):675-677. doi: 10.1684/ejd.2019.3691.
9
Eosinophilic fasciitis (Shulman's disease): review and comparative evaluation of seven patients.
Reumatologia. 2019;57(2):85-90. doi: 10.5114/reum.2019.84813. Epub 2019 Apr 29.
10
Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.
JAAD Case Rep. 2018 Sep 18;4(8):830-832. doi: 10.1016/j.jdcr.2018.06.009. eCollection 2018 Sep.
Zotero 插件